8-K filing — Rein Therapeutics, Inc. (RNTX)
Filed: 2026-09-04 AccNo: 0001193125-26-383726 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rein Therapeutics To Present Data On Inhaled LTI-03 For Idiopathic Pulmonary Fibrosis At European Respiratory Society 2026 Congress
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.